Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

US8183234B2 · kind B2 · utility

Assignee

• Piramal Life Sciences Limited · IN

Inventors

• Bansi Lal · Yellandu, IN
• Swati Bal-Tembe · Mumbai, IN
• Usha Ghosh · Mumbai, IN
• Arun Kumar Jain · Mumbai, IN
• Tulsidas More · Mumbai, IN
• Anil Ghate · Thane, IN
• Jacqueline Trivedi · Mumbai, IN
• Sapna Parikh · Mumbai, IN

Key dates

• Filing date: Jun 30, 2010
• Grant date: May 22, 2012
• Expiry date: Jun 30, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Guanidine derivatives having a condensed tricyclic ring of formula 1:are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidinocarbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.